Literature DB >> 22225856

Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time.

Brynja R Gudmundsdottir1, Charles W Francis, Alexia M Bjornsdottir, Moa Nellbring, Pall T Onundarson.   

Abstract

Vitamin K antagonists (VKA) are monitored with prothrombin time (PT) based assays that are equally sensitive to reductions in factors II, VII or X. We compared the effect of vitamin K dependent (VKD) coagulation factors on PT and also on rotational thromboelastometric (ROTEM) parameters. The PT was equally sensitive to reductions in factors II, VII or X but ROTEM parameters correlated poorly with the PT in anticoagulated patients´ plasmas. ROTEM parameters were more affected by mild and moderate reductions in FII or FX than by FVII or FIX which had little influence except at very low coagulant activity. We developed a modified PT that was sensitive only to reductions in factors II and X. The Fiix-PT (Fiix-INR) correlated well with PT (INR) but the Fiix-INR fluctuated less than the INR in an anticoagulated patient reflecting its insensitivity to FVII. The ROTEM results suggest that mild to moderate reductions in factors II or X are more important during clot formation than factors VII or IX. Reductions in FII and X may better reflect anticoagulation with VKA than FVII or IX. The new Fiix-PT may more accurately reflect the degree of therapeutic anticoagulation in patients treated with VKA than the current PT which is subject to a confounding variation caused by FVII.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22225856     DOI: 10.1016/j.thromres.2011.12.013

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  The need for an adapted initiation nomogram during Fiix prothrombin time monitoring of warfarin.

Authors:  Pall T Onundarson; Brynja R Gudmundsdottir
Journal:  J Thromb Thrombolysis       Date:  2019-11       Impact factor: 2.300

2.  Effect of haematocrit on fibrin-based clot firmness in the FIBTEM test.

Authors:  Cristina Solomon; Niels Rahe-Meyer; Herbert Schöchl; Marco Ranucci; Klaus Görlinger
Journal:  Blood Transfus       Date:  2012-11-20       Impact factor: 3.443

3.  Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial.

Authors:  Alma Rut Oskarsdóttir; Brynja R Gudmundsdottir; Olafur S Indridason; Sigrun H Lund; David O Arnar; Einar S Bjornsson; Magnus K Magnusson; Hulda M Jensdottir; Brynjar Vidarsson; Charles W Francis; Pall T Onundarson
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

4.  Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2.

Authors:  Ravi Sarode; Katsuyuki Fukutake; Masahiro Yasaka; Michael A Tortorici; Antoinette Mangione; Marc Pfister; Adam Cuker
Journal:  Blood Adv       Date:  2020-09-08

5.  Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study.

Authors:  Alma R Oskarsdottir; Brynja R Gudmundsdottir; Hulda M Jensdottir; Bjorn Flygenring; Ragnar Palsson; Pall T Onundarson
Journal:  Blood       Date:  2021-05-20       Impact factor: 22.113

Review 6.  "In Less than No Time": Feasibility of Rotational Thromboelastometry to Detect Anticoagulant Drugs Activity and to Guide Reversal Therapy.

Authors:  Vittorio Pavoni; Lara Gianesello; Duccio Conti; Piercarlo Ballo; Pietro Dattolo; Domenico Prisco; Klaus Görlinger
Journal:  J Clin Med       Date:  2022-03-04       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.